Blood:多发性骨髓瘤17p缺失的亚克隆比例越高,患者预后越差

2019-02-07 MedSci MedSci原创

缺失跨域TP53基因的染色体17p(del17p)与多发性骨髓瘤(MM)的预后不良相关,但del17p癌克隆分数(CCF)的预后意义尚不明确。Anjan Thakurta等人对一大批携带不同del17p水平的新诊断的MM (NDMM)患者进行了统一的细胞学评估。CCF的增殖变化与生存期缩短相关,数据库中将0.55CCF设定为健康阈值。根据0.55CCF阈值进行分层,与低风险患者相比,高风险患者预后

缺失跨域TP53基因的染色体17p(del17p)与多发性骨髓瘤(MM)的预后不良相关,但del17p癌克隆分数(CCF)的预后意义尚不明确。

Anjan Thakurta等人对一大批携带不同del17p水平的新诊断的MM (NDMM)患者进行了统一的细胞学评估。CCF的增殖变化与生存期缩短相关,数据库中将0.55CCF设定为健康阈值。

根据0.55CCF阈值进行分层,与低风险患者相比,高风险患者预后差,差异且具有统计学差异;高风险和低风险患者的中位无进展存活期(PFS)和总体存活期(OS)分别为14和32个月、23.1和76.2个月。

对NDMM患者的全外显子测序数据进行分析发现,除了del17p CCF阈值,TP53的缺失/突变对高风险分层也至关重要。此外,研究人员对三个数据库进行Meta分析验证了CCF阈值对预测PFS和OS的稳定性。

择总而言之,本研究表明FISH和基于测序的方法的可行性:1)检测TP53缺失,2)评估CCF,3)明确0.55CFF阈值和TP53缺失对识别预后不良的携带del17p的NDMM患者至关重要。

原始出处:

Anjan Thakurta,et al. High sub-clonal fraction of 17p deletion is associated with poor prognosis in Multiple Myeloma. Blood 2019 :blood-2018-10-880831; doi: https://doi.org/10.1182/blood-2018-10-880831 

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889975, encodeId=2d4d18899e5eb, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Sep 08 20:15:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660184, encodeId=a17e1660184f1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Dec 30 20:15:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692037, encodeId=0758169203e08, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jul 16 11:15:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936889, encodeId=9eb3193688905, content=<a href='/topic/show?id=78042423365' target=_blank style='color:#2F92EE;'>#亚克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24233, encryptionId=78042423365, topicName=亚克隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Sep 20 05:15:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360216, encodeId=8bbf3602161a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 08 22:00:49 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-09-08 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889975, encodeId=2d4d18899e5eb, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Sep 08 20:15:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660184, encodeId=a17e1660184f1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Dec 30 20:15:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692037, encodeId=0758169203e08, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jul 16 11:15:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936889, encodeId=9eb3193688905, content=<a href='/topic/show?id=78042423365' target=_blank style='color:#2F92EE;'>#亚克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24233, encryptionId=78042423365, topicName=亚克隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Sep 20 05:15:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360216, encodeId=8bbf3602161a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 08 22:00:49 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-12-30 aids221
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889975, encodeId=2d4d18899e5eb, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Sep 08 20:15:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660184, encodeId=a17e1660184f1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Dec 30 20:15:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692037, encodeId=0758169203e08, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jul 16 11:15:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936889, encodeId=9eb3193688905, content=<a href='/topic/show?id=78042423365' target=_blank style='color:#2F92EE;'>#亚克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24233, encryptionId=78042423365, topicName=亚克隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Sep 20 05:15:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360216, encodeId=8bbf3602161a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 08 22:00:49 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889975, encodeId=2d4d18899e5eb, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Sep 08 20:15:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660184, encodeId=a17e1660184f1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Dec 30 20:15:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692037, encodeId=0758169203e08, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jul 16 11:15:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936889, encodeId=9eb3193688905, content=<a href='/topic/show?id=78042423365' target=_blank style='color:#2F92EE;'>#亚克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24233, encryptionId=78042423365, topicName=亚克隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Sep 20 05:15:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360216, encodeId=8bbf3602161a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 08 22:00:49 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1889975, encodeId=2d4d18899e5eb, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Sep 08 20:15:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660184, encodeId=a17e1660184f1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Dec 30 20:15:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692037, encodeId=0758169203e08, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jul 16 11:15:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936889, encodeId=9eb3193688905, content=<a href='/topic/show?id=78042423365' target=_blank style='color:#2F92EE;'>#亚克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24233, encryptionId=78042423365, topicName=亚克隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Sep 20 05:15:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360216, encodeId=8bbf3602161a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 08 22:00:49 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-02-08 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

ASH大会盘点︱邱录贵教授:多发性骨髓瘤靶向新药与免疫治疗新近进展

2018年12月1-4日,全球最具影响力的血液学盛会美国血液学会(ASH)年会如约而至。在这场国际顶级血液学大咖云集、汇聚全球最新学术动态及临床研究的饕餮盛宴上,中国医学科学院血液病医院邱录贵教授,与广大医学同道分享来自多发性骨髓瘤(MM)领域的最新进展,并就国内MM诊断及治疗策略的现状及挑战进行了精彩解析。

2018ASH进展盘点:邱录贵教授:多发性骨髓瘤基础与临床进展齐飞,中国贡献举足轻重

2018年度美国血液学年会(ASH)已于12月1-4日在美国圣地亚哥顺利举行。此次ASH会议上,多发性骨髓瘤(MM)研究无论在临床试验还是基础研究方面都取得了令人瞩目的成就。

JCO:多发性骨髓瘤的自体移植,巩固和维持治疗

最近,研究人员设计了一项前瞻性,随机,III期研究,通过比较AHCT,串联AHCT(AHCT / AHCT),AHCT以及随后的4个len,bortezomib和地塞米松(RVD; AHCT + RVD)周期,测试其他干预措施以改善PFS。

吴德沛教授:自体干细胞移植在多发性骨髓瘤治疗中的地位稳固如初

2018年12月1-4日,美国血液学年会(ASH)在美国·圣地亚哥隆重召开。作为第二大血液系统恶性疾病,多发性骨髓瘤(MM)的诊治水平近年来得到大大提高,多种新型药物的问世显着改善了患者的生存预后。

Lancet:自体干细胞移植后Ixazomib的维持治疗

研究认为,自体干细胞移植后Ixazomib治疗可延长患者无进展生存期

路瑾教授:多发性骨髓瘤领域亮点回顾

在刚刚结束的第60届美国血液学会(ASH)年会上,多发性骨髓瘤(MM)领域的进展值得关注,亮点内容涉及从MM的诊断,到冒烟型骨髓瘤(SMM)的管理,以及症状性MM的单抗治疗和维持治疗等话题。